Xarelto (rivaroxaban) / J&J 
Welcome,         Profile    Billing    Logout  
 97 Diseases   247 Trials   247 Trials   14602 News 


«12...2829303132333435363738...170171»
  • ||||||||||  aspirin / Generic mfg.
    LEAP Pilot: Low Molecular Weight Heparin Vs. Aspirin Postpartum (ENMCC - Great Hall BC) -  Nov 4, 2022 - Abstract #ASH2022ASH_1519;    
    Demonstration of non-inferiority of ASA and LMWH to LMWH will lead to a shorter course of LMWH postpartum, potentially reducing bleeding risk, need for subcutaneous injections, as well as cost, while improving quality of life. If the definitive trial does not show non-inferiority, the results will provide evidence that six weeks of postnatal thromboprophylaxis with LMWH is warranted.
  • ||||||||||  rivaroxaban / Generic mfg.
    Retrospective data, Journal:  Pooled Analysis of Rivaroxaban therapy for acute venous thromboembolism in FIRST registry, SWIVTER and DRESDEN NOAC registry. (Pubmed Central) -  Nov 4, 2022   
    Overall treatment outcomes were consistent with the results of the phase III rivaroxaban trials in VTE treatment, indicating that the use of rivaroxaban offers acceptable treatment results also in routine care. However, we observed significant differences in patient characteristics and management patterns across Switzerland, the United Kingdom, and Germany, limiting direct comparisons of unadjusted outcome event rates between registries.
  • ||||||||||  rivaroxaban / Generic mfg., warfarin / Generic mfg., apixaban / Generic mfg.
    Retrospective data, Journal:  Evaluation of the use of direct oral anticoagulants for the management of heparin-induced thrombocytopenia. (Pubmed Central) -  Nov 2, 2022   
    Historically, treatment of heparin-induced thrombocytopenia (HIT) includes a non-heparin parenteral anticoagulant with bridging to warfarin once platelets recover...The most frequently used DOAC was apixaban at the VTE treatment dose [15 (57.7%)] followed by the reduced dose of apixaban [5 (19.2%)]...Most patients received a parenteral anticoagulant prior to DOAC initiation. All patients managed with a DOAC as initial treatment achieved platelet recovery within 30 days of HIT diagnosis.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Retrospective data, Review, Journal:  Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis. (Pubmed Central) -  Nov 2, 2022   
    For preventing and treating VTE, in terms of VTE occurrence and major bleeding, apixaban had the lowest risk; in terms of clinically relevant non-major bleeding, LMWH had the lowest risk, followed by apixaban. Generally, apixaban is the most efficient and safest DOAC and presents better efficacy and relatively low bleeding risk among the VTE prevention and treatment drugs for patients with cancer.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Journal:  TAVR: nemesis of NOACs? (Pubmed Central) -  Nov 2, 2022   
    These findings remained robust after multivariate analysis. In summary, twice-daily and once-daily NOACs did not differ regarding bleeding complications in a hypothesis generating real-world cohort of TAVR patients with AF.
  • ||||||||||  rivaroxaban / Generic mfg., clopidogrel / Generic mfg.
    Review, Journal:  Antithrombotic therapy in peripheral arterial disease. (Pubmed Central) -  Nov 1, 2022   
    Recently, the concept of dual pathway inhibition (low-dose rivaroxaban plus acetylic salicylic acid (ASA) has been tested in the COMPASS and VOYAGER-PAD trial...In patients with high bleeding risk, a single antiplatelet drug (preferable clopidogrel) is indicated...Antithrombotic treatment reduces MACE and MALE and is recommended in all patients with PAD. Individual bleeding risk should always be considered based on the current data situation and an individual benefit-risk assessment must be carried out.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo, Fragmin (dalteparin sodium) / Pfizer, Eisai
    Review, Journal:  Safe and effective treatment of venous Thromboembolism associated with Cancer: focus on direct Oral Anticoagulants in Asian patients. (Pubmed Central) -  Oct 29, 2022   
    An increased risk of major gastrointestinal bleeding was evident with edoxaban or rivaroxaban, but not apixaban, versus dalteparin in the clinical trials, suggesting that apixaban could be a safe alternative to LMWH in patients with gastrointestinal malignancies. Determining the optimal anticoagulant therapy for patients with CAT requires careful consideration of bleeding risk, tumor type, renal function, drug-drug interactions, financial costs, and patients' needs and preferences.
  • ||||||||||  rivaroxaban / Generic mfg., apixaban / Generic mfg.
    Journal:  Assessment of Direct Oral Anticoagulant Use at a Community Teaching Hospital. (Pubmed Central) -  Oct 29, 2022   
    The most common reason for an inappropriate order for apixaban was due to atrial fibrillation dosing, and the most common reason for an inappropriate rivaroxaban order was due to dose-indication mismatch. There were 30 pharmacist clinical interventions on DOAC orders that were documented during the 6-month period, and the most common reason for a pharmacist intervention was duplication with another anticoagulant.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Preclinical, Journal:  Novel Ex Vivo DOAC Removal Methods Reduce Interference in Lupus Anticoagulant Testing. (Pubmed Central) -  Oct 28, 2022   
    In conclusion, DOAC removal ex vivo reduces false positives in LAC screening. DOAC removal halved the need for confirmation or mixing tests- Although a subset of patients would require further testing, DOAC removal reduces unnecessary repeated LAC testing.
  • ||||||||||  Bevyxxa (betrixaban) / AstraZeneca
    Journal:  Current and emerging drug strategies for the prevention of venous thromboembolism in acutely ill medical inpatients. (Pubmed Central) -  Oct 28, 2022   
    Low molecular weight heparin and fondaparinux have long been used for inhospital prophylaxis for patients at increased risk of VTE...Thanks to the potentially favorable safety profile, factor XI inhibitors may play a role in the prevention of VTE in this setting. The expert opinion section discusses pharmacological properties, prophylaxis trials, and potential clinical applications of this novel class of drugs.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Review, Journal:  Direct Oral Anticoagulants for the Prevention and Acute Treatment of Cancer-Associated Thrombosis. (Pubmed Central) -  Oct 28, 2022   
    Recent guidelines suggest the DOACs for the treatment of CAT in selected cancer patients (eg, low bleeding risk, no luminal gastrointestinal or genitourinary malignancies, no interfering medications). The DOACs are also suggested for primary thromboprophylaxis in selected ambulatory cancer patients at high risk of VTE (eg, Khorana score ≥2 prior to starting new chemotherapy, low bleeding risk, no interfering medications).
  • ||||||||||  rivaroxaban / Generic mfg., enoxaparin sodium / Generic mfg.
    Retrospective data, Journal:  Extended Thromboprophylaxis in Hospitalized Patients with Heart Failure: A Post Hoc Analysis of the MAGELLAN Study. (Pubmed Central) -  Oct 28, 2022   
    A significant 36% reduction in the composite endpoint of asymptomatic proximal deep vein thrombosis (DVT) in the lower extremity, symptomatic DVT in the lower extremity (proximal or distal), symptomatic nonfatal pulmonary embolism, and venous thromboembolism-related death was observed with rivaroxaban. Major bleeding was low in both groups and not significantly increased with rivaroxaban.
  • ||||||||||  rivaroxaban / Generic mfg., warfarin / Generic mfg.
    Retrospective data, Review, Journal:  Efficacy and Safety of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Meta-Analysis. (Pubmed Central) -  Oct 28, 2022   
    Our study revealed that VKAs remain the gold standard for the management of APS, especially triple-positive APS. DOACs, particularly rivaroxaban, are not as effective in preventing recurrent thromboembolism in high-risk APS patients. Further studies are needed to evaluate the role of DOACs apart from rivaroxaban with a focus on their efficacy in the management of isolated or double-positive APS.
  • ||||||||||  rivaroxaban / Generic mfg., aspirin / Generic mfg.
    Journal:  Best Medical Treatment: What About the COMPASS Trial Strategy? (Pubmed Central) -  Oct 27, 2022   
    DOACs, particularly rivaroxaban, are not as effective in preventing recurrent thromboembolism in high-risk APS patients. Further studies are needed to evaluate the role of DOACs apart from rivaroxaban with a focus on their efficacy in the management of isolated or double-positive APS. No abstract available
  • ||||||||||  Fraxiparine (nadroparin) / Aspen
    Enrollment open, Trial completion date, Trial primary completion date, Metastases:  Anticoagulation for Advanced Cirrhotic Patients After TIPS (clinicaltrials.gov) -  Oct 25, 2022   
    P=N/A,  N=254, Recruiting, 
    Active, not recruiting --> Completed Unknown status --> Recruiting | Trial completion date: Dec 2020 --> Dec 2024 | Trial primary completion date: Dec 2020 --> Dec 2023